Immunosuppressants Market Report 2026

Immunosuppressants Market Overview

• Immunosuppressants market size has reached to $34.05 billion in 2025 • Expected to grow to $62.64 billion in 2030 at a compound annual growth rate (CAGR) of 13.1% • Growth Driver: Rising Autoimmune Disease Cases • Market Trend: Market Shift Toward Biosimilars To Improve Access And Affordability In Immunosuppressive Therapies • North America was the largest region in 2025.

What Is Covered Under Immunosuppressants Market?

Immunosuppressant refers to a medication that prevents the immune system from attacking healthy cells and tissues. These medications are used to stop transplant rejection in recipients of stem cell and organ transplants. The medications also address the symptoms of autoimmune diseases. Immunosuppressants market are potent medications that need to be carefully monitored to prevent side effects. The main classes of drugs in the immunosuppressants market are corticosteroids, monoclonal antibodies (MABs), calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different indications include organ transplantation, autoimmune disorders, and non-autoimmune inflammatory diseases and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Immunosuppressants Market Growth Forecast?

The immunosuppressants market size is expected to see rapid growth in the next few years. It will grow to $62.64 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to rising transplant survival rates, growth of monoclonal antibody therapies, increased monitoring technologies adoption, development of safer drug classes, expanding access in emerging markets. Major trends in the forecast period include rising use of immunosuppressants in organ transplantation, shift toward targeted and biologic immunosuppressants, growing focus on long-term safety and monitoring, expansion of immunosuppressant use in autoimmune diseases, increased adoption of personalized immunosuppression regimens.

Global Immunosuppressants Market Segmentation

1) By Drug Class: Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Other Drug Classes 2) By Indication: Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone 2) By Monoclonal Antibodies (mAbs): Anti-TNF Agents, Anti-CD20 Agents, Anti-IL-6 Agents 3) By Calcineurin Inhibitors: Cyclosporine, Tacrolimus 4) By mTOR Inhibitors: Sirolimus, Everolimus 5) By Anti-Proliferative Agents: Azathioprine, Mycophenolate Mofetil 6) By Other Drug Classes: Co-Stimulation Blockers, JAK Inhibitors

What Is The Driver Of The Immunosuppressants Market?

The increase in instances of autoimmune diseases is expected to propel the growth of the immunosuppressants market. Autoimmune diseases are a broad group of disorders characterized by an abnormal immune response in which the immune system mistakenly attacks and damages healthy cells, tissues, and organs. Immunosuppressant medications can benefit autoimmune diseases like rheumatoid arthritis by reducing the overactive immune response, which helps alleviate symptoms and slow down disease progression. This is a common disease in the elderly population.For instance, in February 2024 according to the Arthritis Australia is a Australia-based non-profit organization In 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Therefore, the increase in instances of autoimmune diseases will drive the immunosuppressants industry.

Key Players In The Global Immunosuppressants Market

Major companies operating in the immunosuppressants market are Pfizer Inc., Johnson & Johnson Services Inc., F Hoffmann La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Co., Mylan Laboratories Inc., Teva Pharmaceuticals USA Inc., Astellas Pharma Inc., Sandoz Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals plc, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Fresenius Kabi USA, Lupin Pharmaceuticals Inc., Strides Pharma Inc., Accord Healthcare Ltd., RPG Life Sciences Limited, Genzyme Transgenics Corp., Apotex Inc.

Global Immunosuppressants Market Trends and Insights

Major companies operating in the immunosuppressants market are focusing on developing advanced biologic and biosimilar therapies to improve treatment accessibility, reduce patient costs, and enhance long-term disease management for autoimmune disorders. These innovations aim to deliver comparable efficacy and safety to originator biologics while expanding therapeutic options across conditions such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease. For instance, in January 2023, Amgen Inc., a US-based biopharmaceutical company, launched AMJEVITA, the first biosimilar to HUMIRA in the United States. This launch marks a significant milestone in the immunosuppressants market, as it introduces greater competition, enhances affordability, and supports broader patient access to biologic treatments. It is expected to accelerate biosimilar adoption across autoimmune disease therapies and stimulate further innovation in cost-effective immunosuppressant solutions.

What Are Latest Mergers And Acquisitions In The Immunosuppressants Market?

In June 2023, Merck & Co., Inc., a US-based global biopharmaceutical company, completed the acquisition of Prometheus Biosciences, Inc. for an undisclosed amount. Through this acquisition, Merck aims to strengthen its immunology pipeline by integrating Prometheus’ precision therapeutics and biomarker-driven drug development platforms, accelerating the advancement of targeted treatments for immune-mediated diseases. Prometheus Biosciences, Inc. is a US-based biotechnology company specializing in precision medicines for autoimmune conditions.

Regional Insights

North America was the largest region in the immunosuppressants market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Immunosuppressants Market?

The immunosuppressants market consists of sales of induction drugs, maintenance drugs, corticosteroids, and calcineurin inhibitors. Values in this market are ""factory gate values,"" that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Immunosuppressants Market Report 2026?

The immunosuppressants market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the immunosuppressants industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.